“I have a tremendous amount of respect for the research but it’s a completely sanitized, you know, sterilized subject pool. There’s all kinds of exclusion criteria and so it’s interesting, it gets a little bit more murky when you start to say well we’re going to study alcohol use disorder with co-morbid depression, right, so they you have to sort of like… how do we know they don’t have PTSD, dissociative disorder or some other thing, are they excluded or not. It’s interesting because psilocybin can be used for a number of conditions,” says Dr. Barnett, Psy.D.
No one clinical trial or piece of research can tell you anything for certain. The more a result is replicated, the more believable it becomes… just because a study comes from a pioneering, high-quality institution doesn’t mean you should blindly trust it. For clinical research, the multi-centre, randomised, placebo-controlled trial is king. Almost all psychedelic research is not this (yet). Initial trials take place in one institution. That’s fine, but it doesn’t say anything about whether the treatment works beyond that institution. For that, you need a multi-centre trial.
Original Article (The Conversation & Psychedelics Today):
Psychedelic drugs: how to tell good research from bad & Contexts of use: exploring the Various paradigms of psychedelics
Artwork Fair Use: Bratislavská župa